Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...
Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...
1d
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...
Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback